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Objectives: The Voltage Dependent Anion-Selective Channel (VDAC), the most abundant protein of the outer mitochondrial membrane (OMM), 
forms the major conduit for metabolite transport across this membrane. It has also been shown to be involved in cell death signalling through 
interaction with other proteins like Hexokinase and by mediating release of apoptogenic proteins like cyt c from mitochondria. As in case of other 
channel proteins, functional characterization of purified reconstituted protein by using electrophysiological techniques can be used in development 
of VDAC targeted drugs. Here we report electrophysiological properties of VDACs (one of the target for cancerous cells) purified from different 
sources. 
Methods: Human VDAC1 and rice VDAC4 were heterologously expressed and purified from E. coli BL21 (DE3)-pLysS, while rat and yeast VDACs 
were purified from mitochondria. Electrophysiological studies of all VDACs were done by using BLM and the data was analysed by using pCLAMP 10 
(Axon Instruments). 
Results: VDACs purified from both the sources showed conserved voltage dependence and channel conductance, however they showed significant 
difference in dynamics. VDAC purified from mitochondria had relatively short occupancy of each electrophysiological state compared to protein 
purified from inclusion bodies. 
Conclusion: Our results suggest that the source of purified protein could be critical for some aspects of channel function. 
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INTRODUCTION 
The Voltage Dependent Anion Channel (VDAC) is the most abundant 
Outer Mitochondrial Membrane (OMM) protein and is the principal 
route for transport of metabolites from mitochondria to cytosol and 
vice versa. Recently many studies have established that VDAC is an 
important component of many signalling pathways underlying 
pathophysiological conditions including cancer and 
neurodegeneration [1-9]. One hallmark of these pathophysiological 
conditions is perturbation of the interactions between VDAC and its 
cellular partners [4, 10-18]. For example, the Warburg Effect in 
cancer features enhanced VDAC-Hexokinase (HxK) interactions 
which correlate with elevated glycolysis even under normoxic 
conditions[19-21]. Similarly, interaction of VDAC with peripheral 
benzodiazepine receptor (PBR) has been shown to be important for 
controlling cell death [8, 22-26]. Apart from its interaction with other 
proteins, overexpression and oligomerization of VDAC has also been 
shown to be important for induction of cell death [27-30]. As a result 
VDAC has been receiving attention as an unexploited drug target in 
recent years. 3-bromopyruvate, which controls cell death by 
disrupting VDAC-HxK interaction, is in phase I clinical trials [31]. 
VDACs purified from a variety of sources have been characterized 
using circular dichroism (CD) [32], nuclear magnetic resonance 
(NMR)[33] and electrophysiological techniques like the planar 
bilayer membrane (BLM)[34-36]. CD spectra establish that all 
characterized VDACs comprise predominantly β sheet with a small 
helical content [32, 36].  
Studies on protein reconstituted into planar bilayers show that VDAC 
forms large conductance (3-5 nS) pores which are slightly anion 
selective in open State[34-36]. The pore conductance is maximal 
under zero field conditions - i.e. in the absence of an applied electric 
field - and decreases on the imposition of high membrane potentials, 
hence the name. The voltage-dependent decrease in conductance is 
associated with the population of subconductance states which have 
permeability characteristics that differ from the Open State populated 
at zero fields. Binding of physiological partners like hexokinase [21], 
tubulin [37-39] or Bcl2 [29] as well as pharmacological agents like 
4,4'-Diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) [40] and 
Ruthenium Red [21, 41] result in significant changes in 
electrophysiological characteristics. Thus, electrophysiological 
characterization on planar membranes can be used to identify 
putative interacting partners and pharmacological agents. VDAC 
isoforms from many organisms ranging from fungi to mammals have 
been purified. The protein is either purified from mitochondria 
directly or is heterologously expressed in bacteria or yeast. In this 
study we have compared electrophysiological characteristics of 
human, rat, yeast and rice VDAC isoform purified from different 
sources. We have observed many similarities along with some 
significant differences which could be of importance for 
pharmacological characterization of potential VDAC based drugs. 
MATERIAL AND METHODS 
Cloning of hVDAC1  
hVDAC1 gene was amplified from hVDAC1- pBS (gifted from Prof. 
Michael Forte) by using forward primer with BamHI site 
AAAGGGATCCTGGCTGTGCCAC and reverse primer with XhoI site 
ACCGCTCGAGTGCTTGAAATTCC. The PCR product, which had 
hVDAC1 cDNA without a stop codon, was cloned into pET21a(+) 
vector in frame with His-tag, between BamHI and XhoI sites. Clones 
with hVDAC1-His6x-pET21a(+) were confirmed by sequencing. 
OsVDAC4-His6x-pET-20b+ construct was developed as described 
earlier in Godbole et al [36]. 
Bacterial expression and purification of OsVDAC4 and hVDAC1  
OsVDAC4-His6x-pET-20b+ and hVDAC1-His6x-pET21a(+) constructs 
were transformed into E. coli host strain BL21 (DE3)-pLysS and 
grown in the presence of 100 µg/ml ampicillin and 25 µg/ml 
chloramphenicol at 37o
36
C. OsVDAC4 and hVDAC1 protein were 
purified by the protocol published in Godbole et al [ ] with some 
modifications. Briefly, expression of hVDAC1-His6x was induced by 
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addition of 1mM IPTG to transformed bacterial culture grown at 37oC 
to a final A600
Mitochondria were isolated from rat and yeast following methods 
published by Marco Colombini [
 of 0.4 - 0.5. After 3 hrs, the cells were harvested and 
lysed using 20 ml of lysis buffer (50mM TrisHCl pH-8, 2mM EDTA, 
20% sucrose, 12.5ug/ml lysozyme) followed by sonication. Inclusion 
bodies were separated from the cell lysate then solubilised in buffer 
containing 6M GnHCl. Protein was purified using Cobalt-Mac column 
(Co-Mac, Novagen USA) in HPLC. Protein fractions were collected in a 
gradient of 0mM and 100mM Imidazole with 4.5M GnHCl, 100mM 
NaCl, 20mM tris-HCl pH8.0. Protein concentration was measured by 
Bradford assay (Bangalore Genei, Bangalore). Protein fractions were 
concentrated to 6 – 8 mg/ml by centrifugation in Centricon 30 tubes. 
LDAO was added to a final concentration of 2% and GnHCl removed 
by dialysis against loading buffer. Proteins were stored at -80°C at a 
concentration of 1– 5 mg/ml. 
Purification of VDAC from Rat liver mitochondria and from Yeast 
mitochondria 
42] and Gunther et al [43], 
respectively. Both purified mitochondrial pellets were incubated for 
30 min at 4°C in solubilisation buffer (10mM tris pH 7, 1mM HEPES, 
0.15mM PMSF, 2% LDAO, protease cocktail). Solubilized 
mitochondria were centrifuged at 20000 x g for 10 min at 4°C. 
Supernatant was loaded on dry packed column of 
hydroxyapatite/celite (2:1). Flow through and other fractions were 
collected. VDAC was found in flow through. Amount of VDAC in 
selected fractions was estimated by Bradford assay (Bangalore Genei, 
Bangalore). The fractions were concentrated by using Centricon 30 
tubes to adjust concentration of VDAC to 1-5mg/ml. The protein was 
stored at -80°C. 
Planar Bilayer Lipid Membrane (BLM) experiment 
Planar BLM experiments were performed as described in Godbole et 
al [36]. Briefly, detergent solubilized protein was incubated with 10 
volumes of cholesterol or β-sitosterol (1 mg/ml) in BLM buffer 
containing 2% LDAO on ice for 30 min. 6-13 pmols of the protein was 
added on cis side of chamber with stable BLM. Upon insertion of 
channel, voltage-clamp recording was performed using a setup 
having BC-525C amplifier (Warner Instruments, LLC, Hamden, CT, 
USA) and Digidata 322 (Axon Instruments/Molecular Devices, USA). 
The data was analysed by using pCLAMP 10 (Axon Instruments). 
RESULTS AND DISCUSSION 
Purification of VDAC 
In this study, as described in material and methodsdescribed in 
material and methods, we have used previouslypublished protocols 
to purify VDAC isoforms from four different organisms namely rat 
VDAC (rVDAC), yeast VDAC (yVDAC), human VDAC1 (hVDAC1) and 
rice VDAC4 (OsVDAC4). rVDAC and yVDAC were isolated from 
mitochondria from rat liver and yeast cells respectively (Fig1A,B). 
hVDAC1 and OsVDAC4 were heterologously expressed in E. coli 
BL21(DE3) and purified from inclusion bodies (Fig1C,D). While 
protein could be purified both from mitochondria and from inclusion 
bodies, the yield was significantly greater in the latter. 
Electrophysiological characteristic of VDACs  
All four purified proteins inserted into 1,2-diphytanoyl-sn-glycero-3-
phosphocholine (DPhPC) bilayers and single channels could be 
characterized in all the cases. Prior incubation of proteins at a 
concentration of 6-13 pmols/ml in buffer containing 1 mg/ml of 
appropriate sterol and 2% LDAO was necessary for proper channel 
formation. Channel conductance and voltage dependence of all VDACs 
was in accordance with reported values. In large part, voltage 
dependence is symmetric for all four VDACs and is thus similar to 
previously reported VDACs but differs sharply from voltage gated 
cation channels [44].  
Intriguingly, while single channel conductance and the overall 
voltage-dependence of transitions into subconductance states were 
broadly similar for all the tested VDACs, the dynamics we observe is 
strikingly different (Table1). Proteins purified from mitochondria 
display rapid transitions between substates at the appropriate 
voltages (Fig 2A and B), whereas the proteins purified from inclusion 
bodies stay in a given substate for an extended period of time before 
sampling another conductance state (Fig 2C and D). 
 
Fig. 1: Purification of VDACs from different sources. (A) rVDAC 
purified from rat liver mitochondria. (B) yVDAC from yeast 
Mitochondria, (C) hVDAC1 from bacterial inclusion bodies.(D) 
OsVDAC4 from bacterial inclusion bodies. 
 
 
Fig. 2: Functional characterization of VDACs purified from 
different sources by using BLM. Current traces were observed in 
response to applied Voltage. (A) Rat VDAC starts transition from 
30mV and shows many transitions at higher potential. (B) Yeast 
VDAC shows many transitions like rat VDAC. (C) hVDAC1 shows 
very few transitions at higher potential and that to from 60mV 
and above. (D) OsVDAC4 show very few transitions like hVDAC1. 
Dubey et al. 




Fig. 3: Dwell time of VDACs purified from different sources 
analyzed by pCLAMP-10 software (A) Rat VDAC and (B) yeast 
VDAC shows less dwell time, (C) hVDAC1 and (D) OsVDAC4 have 
high dwell time. 
 
We illustrate this by analysing the dwell times in subconductance 
state 1 (also referred to as the Closed State in many publications). 
Single channels of rVDAC and of yVDAC in membranes held at +60 
mV undergo transition primarily between the Open State and 
Subconductance State 1 (or Closed State). The dwell time histogram 
for Subcondctance State 1 can be fit well with a single exponential 
yielding mean occupancy times of 75.8±6.6 and 103.3±6.3 ms for rat 
and yeast VDACs, respectively (Fig 3A and B).  
Very few transitions were observed with hVDAC1 or OsVDAC4 (Fig 
2C and D). In both cases multiple subconductance States were 
observed. Here the paucity of events precluded an accurate estimate 
of occupancy times, but a rough estimate with the limited number of 
events yields values of 867.4±49.7 and 876.4±37.9 ms (Fig 3C and D).  
The raw data clearly reveals the dramatic difference in dynamics 
between the two sets of proteins (Table1). 
 
Table1: Comparison between VDACs purified from different 
sources in terms of single channel conductance and dwell time. 








Mitochondria 4.36±0.1 75.8±6.6 
Yeast 
VDAC 




OsVDAC4  Bacterial 
Inclusion body 
4.6 ± 0.3 ~876 
 
DISCUSSION 
Ion channels are membrane proteins responsible for transport of ions 
across the membranes. Open Reading Frames encoding as many as 
400 different ion channels are present in the human genome, but 
relatively few of them have been characterized till date[45]. 
Mutations in channel genes leading to loss of function or altered 
function result in a variety of diseases termed channelopathies [46]. 
Ion channels have thus emerged as popular drug targets.  
Functional characterization of ion channels is generally done by 
electrophysiological techniques. Several electrophysiological 
parameters like channel conductance, ion selectivity, open 
probability and dwell time (opening-closing kinetics) can be studied 
by using appropriate techniques. Any channel modifying agent would 
affect one or more of these characteristics. Thus a drug candidate can 
be characterized by assessing its ability to alter the channel 
physiology. 
Dwell-time is an important electrophysiological parameter used for 
characterization and standardization of putative channel modifying 
drugs especially with respect to its clinical suitability [47, 48]. For 
example, an efficient excitotoxicity blocker, MK801, was found to be 
clinically unsuitable as it extended the dwell-time of the Glutamate 
receptors of the N-methyl-D-aspartate receptor subtype (NMDAR) 
leading to undesirable effects [49, 50]. 
VDAC is looked at as a promising drug target especially for anti-
cancer drugs [4, 7, 19, 20, 51]. Potential drug molecules affecting 
electrophysiology of VDAC can be efficiently characterized by using 
BLM systems. Our data shows conservation of most of the 
electrophysiological characteristics like conductance and voltage 
dependence of VDAC irrespective of its origin and method of 
purification (Fig 2). This is in agreement with earlier published 
reports [44]. Additionally, we have also looked at dwell time of VDAC 
channels formed by protein purified from different sources. Unlike 
other parameters, dwell-time of the channel differed with source of 
purification (Fig 3). Dwell time of VDAC has not been studied 
commonly. It is, however, the only parameter in the 
electrophysiological arsenal that characterizes channel dynamics. 
Transitions to subconductance states has dramatic effects on 
selectivity (only the Open State has significant permeability to ATP 
and ADP [36, 52]) and has been suggested to influence functioning in 
apoptotic contexts [53]. Further, in a review, Marco Colombini has 
pointed out that VDAC dwell time can be affected when elevated 
voltage is applied for extended durations [54]. Our data demonstrate 
that the two VDACs purified from inclusion bodies have significantly 
slower dynamics than the two purified from their native 
mitochondrial membranes. Published data for rat VDAC purified from 
rat liver mitochondria, and for yeast VDAC purified from 
mitochondria are consistent with our dwell time estimates, although 
this parameter has not been reported on. Additionally, published data 
on mVDAC1 purified from yeast mitochondria after heterologous 
expression show transitions into the Closed State with durations of a 
few hundred milliseconds[21], while those on hVDAC1 [55] and 
mVDAC1 [56] purified from inclusion bodies display very few 
transitions with residence times of the order of a second. mVDAC1 
and hVDAC1 share 99% sequence identity, suggesting that the 
difference in observed physiology could be due to the purification 
protocol.  
Our findings are suggestive of a “memory effect” in VDAC – i.e. the 
observed dynamics of the channel in BLM appears to be strongly 
influenced by the method of purification. As such, it will be important 
to keep in mind the purification protocol when evaluating data on 
VDAC reconstituted into artificial membrane systems 
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